TNFRSF10B and prostate carcinoma: Olaparib may enhance the sensitivity of prostate cancer cells, whether BRCA wild-type or mutant, to NK cells by upregulating the expression of the death receptor TRAIL-R2 on the surface of prostate cancer cells (70).